Legal Advantage Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-19,965
Closed -$1.8M 104
2024
Q4
$1.8M Sell
19,965
-600
-3% -$58.1K 0.95% 35
2024
Q3
$2.03M Sell
20,565
-550
-3% -$54K 1.12% 29
2024
Q2
$1.96M Sell
21,115
-400
-2% -$35.9K 1.13% 31
2024
Q1
$2.04M Sell
21,515
-375
-2% -$34.8K 1.14% 28
2023
Q4
$1.95M Hold
21,890
1.17% 25
2023
Q3
$1.6M Sell
21,890
-700
-3% -$55.9K 1.14% 25
2023
Q2
$1.88M Hold
22,590
1.25% 24
2023
Q1
$1.72M Buy
22,590
+130
+0.6% +$10.8K 1.26% 24
2022
Q4
$1.86M Buy
22,460
+115
+0.5% +$9.31K 1.53% 21
2022
Q3
$1.77M Buy
22,345
+690
+3% +$58.2K 1.66% 18
2022
Q2
$1.61M Buy
21,655
+1,245
+6% +$93.5K 1.57% 19
2022
Q1
$1.83M Hold
20,410
1.38% 26
2021
Q4
$2.29M Sell
20,410
-470
-2% -$56.7K 1.55% 20
2021
Q3
$2.63M Buy
20,880
+600
+3% +$77.3K 1.76% 19
2021
Q2
$2.75M Hold
20,280
1.88% 17
2021
Q1
$2.75M Buy
20,280
+100
+0.5% +$15K 2.06% 16
2020
Q4
$2.84M Buy
+20,180
New +$2.58M 2.21% 15

Other funds holding XBI

Legal Advantage Investments's XBI Position: Q1 2025 in Review

Legal Advantage Investments sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 19,965 shares — an estimated $1.8M sold.

Legal Advantage Investments first reported a position in XBI in Q4 2020 and held it in 17 quarters. The position peaked at $2.84M in Q4 2020. 683 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • Legal Advantage Investments reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • Legal Advantage Investments sold 19,965 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $1.8M.
  • Legal Advantage Investments first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 17 quarters.
  • Legal Advantage Investments's State Street SPDR S&P Biotech ETF position peaked at $2.84M in Q4 2020.
  • 683 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Legal Advantage Investments's 13F filing for Q1 2025, filed 13 May 2025.